Breaking News, Collaborations & Alliances

PCI, ChiRhoClin Partner to Avoid Shortage of Critical Diagnostic Drug

The collaboration provided an ample, stable supply of ChiRhoStim, an essential drug for diagnosing pancreatic cancer and exocrine dysfunction.

Author Image

By: Charlie Sternberg

Associate Editor

PCI Pharma Services (PCI), a global contract development and manufacturing organization (CDMO), has joined forces with theranostics specialist ChiRhoClin Inc. to avoid a potential shortage of a critical diagnostic drug used to test for pancreatic disease and cancer.   As a result of this collaboration, an ample, stable supply of ChiRhoStim (Human Secretin for Injection) continues to be available to benefit patients throughout the United States.   ChiRhoClin’s intravenous product, ChiRhoStim,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters